Antidepressant Treatment in Older Adults With Schizophrenia

This study has been completed.
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Sidney Zisook, Veterans Medical Research Foundation Identifier:
First received: October 4, 2002
Last updated: August 6, 2013
Last verified: August 2013
The purpose of this study is to evaluate the safety and effectiveness of citalopram (Celexa) for the treatment of depressive symptoms in middle-aged and elderly patients with schizophrenia.

Condition Intervention
Drug: Citalopram (Celexa)
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Citalopram Augmentation in Older Patients With Schizophrenia

Resource links provided by NLM:

Further study details as provided by Veterans Medical Research Foundation:

Enrollment: 212
Study Start Date: September 2001
Study Completion Date: September 2007
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Participants will take placebo
Drug: Placebo
Placebo for 3 months
Active Comparator: 2
Participants will take citalopram (Celexa)
Drug: Citalopram (Celexa)
Citalopram for 3 months

Detailed Description:

Older people with schizophrenia suffer from greater physical comorbidity, cognitive impairment, and medication side effects compared to their younger counterparts. Unfortunately, little research is available to guide the treatment of subsyndromal depressive symptoms in older adults. This study will compare the antidepressant citalopram to placebo to determine the most effective treatment for reducing depressive symptoms in older patients with schizophrenia

After patients have been on stable treatment with antipsychotic medication for at least 4 weeks, they are randomly assigned to receive antipsychotic medication plus either citalopram or placebo for 3 months. Depressive symptoms and side effects are assessed weekly for the first month, biweekly for the second month, and again at the end of the third month. Cognition, motor and daily functioning, quality of life, and medication adherence are assessed throughout the study.


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Schizophrenia or schizoaffective disorder
  • HAM-D score of 8 or above
  • Antipsychotic medication treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00047450

United States, California
San Diego VA Medical Center
San Diego, California, United States, 92161
United States, Ohio
Veterans Administration Hospital of Cincinnati
Cincinnati, Ohio, United States, 45220
Sponsors and Collaborators
Veterans Medical Research Foundation
National Institute of Mental Health (NIMH)
Principal Investigator: Sidney Zisook, MD University of California, San Diego
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sidney Zisook, Research Scientist, Veterans Medical Research Foundation Identifier: NCT00047450     History of Changes
Obsolete Identifiers: NCT00046098
Other Study ID Numbers: R01MH063931  DATR A4-GPX 
Study First Received: October 4, 2002
Last Updated: August 6, 2013
Health Authority: United States: Federal Government

Keywords provided by Veterans Medical Research Foundation:
Psychotic Disorders

Additional relevant MeSH terms:
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Cholinergic Agents
Cholinergic Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors processed this record on May 25, 2016